Single Vector AAV Approach to Genome Editing in Pompe Disease

被引：0
|
作者：
Arnson, Benjamin [1 ]
Wang, Jason [2 ]
Courtney, David [3 ]
Han, Sang-oh [1 ]
Li, Songtao [1 ]
Cullen, Bryan R. [3 ]
Bursac, Nenad [2 ]
Koeberl, Dwight [1 ]
机构：
[1] Duke Univ, Pediat Med Genet, Durham, NC USA
[2] Duke Univ, Biomed Engn, Durham, NC USA
[3] Duke Univ, Mol Genet & Microbiol, Durham, NC USA
来源：
MOLECULAR THERAPY | 2021年 / 29卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
600
引用
收藏
页码：291 / 291
页数：1
相关论文
共 50 条
  • [1] Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia
    Kang, Hye-Ri
    Waskowicz, Lauren
    Seifts, Andrea M.
    Landau, Dustin J.
    Young, Sarah P.
    Koeberl, Dwight D.
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2019, 13 : 265 - 273
  • [2] Somatic Genome Editing with AAV Vectors Generates and Corrects a Metabolic Disease
    Lagor, William R.
    Jarrett, Kelsey E.
    Lee, Ciaran M.
    Yeh, Yi-Hsien
    Hsu, Rachel H.
    Gupta, Rajat
    Zhang, Min
    Rodriguez, Perla
    Bissig, Karl-Dimiter
    Pownall, Henry J.
    Martin, James F.
    Bao, Gang
    MOLECULAR THERAPY, 2017, 25 (05) : 14 - 14
  • [3] Re-evaluation of AAV vector concentrations for knock-in mouse production with genome editing
    Suzuki, Osamu
    Minako, Koura
    Uchio-Yamada, Kozue
    Sasaki, Mitsuho
    Doi, Yuko
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (03) : S363 - S363
  • [4] The Role of Recombinant AAV in Precise Genome Editing
    Bijlani, Swati
    Pang, Ka Ming
    Sivanandam, Venkatesh
    Singh, Amanpreet
    Chatterjee, Saswati
    FRONTIERS IN GENOME EDITING, 2022, 3
  • [5] Single-Cut Gene Editing Therapy for Duchenne Muscular Dystrophy via a Single AAV Vector
    Li, Guoling
    Lin, Jiajia
    Li, Haisen
    Jin, Ming
    Li, Zhifang
    Shi, Linyu
    Wang, Ning
    Chen, Wanjin
    Yang, Hui
    MOLECULAR THERAPY, 2023, 31 (04) : 461 - 462
  • [6] AAV9 vector encoding hGAA improves synaptic pathology of the neuromuscular junction in Pompe disease
    Falk, D. J.
    Todd, A. G.
    Soustek, M. S.
    Cloutier, D. C.
    ElMallah, M.
    Fuller, D. D.
    Byrne, B. J.
    NEUROMUSCULAR DISORDERS, 2013, 23 (9-10) : 829 - 829
  • [7] AAV-mediated gene therapy of Pompe disease
    Ziegler, RJ
    Bercury, S
    Armentaro, D
    Raben, N
    Cheng, SH
    NEUROMUSCULAR DISORDERS, 2005, 15 (9-10) : 713 - 713
  • [8] In vivo genome editing as an approach to the treatment of genetic disease
    Anguela, Xavier M.
    Sharma, Rajiv
    Li, Hojun
    Haurigot, Virginia
    Bhagwat, Anand
    Davidson, Robert
    Zhou, Shangzhen
    Doyon, Yannick
    Gregory, Philip D.
    Holmes, Michael C.
    High, Katherine A.
    HUMAN GENE THERAPY, 2012, 23 (10) : A8 - A8
  • [9] Early dose response data with homologous recombination-based genome editing approach using a promoterless AAV vector in mice with methylmalonic acidemia
    Zhang, S.
    Bastille, A.
    Taylor, R.
    Liao, J.
    Chiang, K.
    Chau, N.
    HUMAN GENE THERAPY, 2018, 29 (12) : A129 - A129
  • [10] Neural Deficits Contribute to Respiratory Insufficiency in Pompe Disease: A Therapeutic Approach with AAV1
    DeRuisseau, Lara R.
    Mah, Cathryn
    Fuller, David D.
    Byrne, Barry J.
    MOLECULAR THERAPY, 2006, 13 : S344 - S344
12345